Original Article
A retrospective cohort study comparing reconstructive techniques and outcomes in post-mastectomy triple negative breast cancer patients
Translational Breast Cancer Research
2023;
4:
5
(31 January 2023)
Original Article
Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study
Translational Breast Cancer Research
2023;
4:
4
(31 January 2023)
Original Article
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
Translational Breast Cancer Research
2023;
4:
3
(31 January 2023)
Clinical Practice Guideline
Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022
Translational Breast Cancer Research
2023;
4:
2
(31 January 2023)
Meet the Professor
Zefei Jiang: when ideals illuminate reality, more breast cancer patients will benefit from the inclusion of T-DM1 in China’s national medical insurance catalog
Translational Breast Cancer Research
2023;
4:
1
(31 January 2023)
Case Report
Presentation of metastatic breast cancer as a large bowel obstruction in an elderly female with resultant diverting ileostomy: case report
Translational Breast Cancer Research
2022;
3:
38
(31 October 2022)
Original Article: Case Series
Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review
Translational Breast Cancer Research
2022;
3:
37
(31 October 2022)
Editorial
CSCO breast cancer management guidelines 2022: Australian perspective
Translational Breast Cancer Research
2022;
3:
36
(31 October 2022)
Editorial
An engineering feat of small proportions
Translational Breast Cancer Research
2022;
3:
35
(31 October 2022)
Editorial
Differences between Japan and China in perioperative pharmacotherapy of early-stage breast cancer in breast cancer guidelines (2022 edition)
Translational Breast Cancer Research
2022;
3:
34
(31 October 2022)
Review Article
Strategies for the treatment of HER2+ advanced breast cancer based on clinical practice in Chinese patients: a roundtable discussion
Translational Breast Cancer Research
2022;
3:
33
(31 October 2022)
Review Article
A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view
Translational Breast Cancer Research
2022;
3:
32
(31 October 2022)
Original Article
Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study
Translational Breast Cancer Research
2022;
3:
31
(31 October 2022)
Consensus
Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)
Translational Breast Cancer Research
2022;
3:
30
(31 October 2022)
Case Report
Reduction in tumor grade and Ki-67 in postmenopausal patient with node-positive invasive ductal carcinoma following combination hormone replacement therapy cessation: a case report
Translational Breast Cancer Research
2022;
3:
29
(30 July 2022)
Case Report
Metastatic breast cancer in a transgender female with history of mantle field radiation and free silicone breast injections: case report
Translational Breast Cancer Research
2022;
3:
28
(30 July 2022)
Case Report
A case report of gender-affirming mastectomy in a transgender individual with breast cancer
Translational Breast Cancer Research
2022;
3:
27
(30 July 2022)
Review Article
Thoughts on therapy strategy in the era of “after anti-HER2 TKI” in CSCO BC Guidelines 2022
Translational Breast Cancer Research
2022;
3:
26
(30 July 2022)
Review Article
Key points of breast cancer management under public health emergencies
Translational Breast Cancer Research
2022;
3:
25
(30 July 2022)
Original Article
A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K)
Translational Breast Cancer Research
2022;
3:
24
(30 July 2022)
Original Article
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes
Translational Breast Cancer Research
2022;
3:
23
(30 July 2022)
Consensus
CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis
Translational Breast Cancer Research
2022;
3:
22
(30 July 2022)
Editorial
Comments to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022
Translational Breast Cancer Research
2022;
3:
21
(30 July 2022)
Editorial Commentary
New progress in early breast cancer treatment in 2021
Translational Breast Cancer Research
2022;
3:
20
(30 April 2022)
Case Report
Pseudoangiomatous stromal hyperplasia causing massive unilateral breast enlargement—a case report
Translational Breast Cancer Research
2022;
3:
19
(30 April 2022)